Alcon (SWX:ALC), What Is Behind The Fresh Attention?

Alcon stock reacts to US Medicaid drug pricing agreement

New US Medicaid drug pricing agreements involving Alcon (SWX:ALC) and eight other healthcare companies have put the stock in focus for investors assessing potential implications for its eye care drug portfolio.

At around CHF58.30 per share, Alcon has seen short term share price pressure related to the Medicaid headlines, with the 1-day share price return down 0.44% and the year-to-date share price return down 8.25%. In contrast, the 90-day share price return is up 14.18%, while the 1-year total shareholder return is down 7.01%. This suggests that recent momentum has improved, although longer term returns have remained weak.

Compare how Alcon stacks up against other healthcare stocks reacting to policy shifts by scanning our hand picked 257 high quality undervalued stocks .

After the Medicaid driven pullback, followed by a stronger 90 day run, Alcon now sits at an interesting crossroads. Does it make more sense to step in at today's price, or wait for a clearer margin of safety?

Most Popular Narrative: 23.9% Undervalued

With Alcon last closing at CHF58.30 and the most followed narrative pointing to a fair value of CHF76.62, the gap between price and narrative value is clear enough to pay attention to.

Accelerated new product launches including Unity VCS (next-gen surgical platform), PanOptix Pro (premium IOL), Tryptyr (first-in-class dry eye Rx), Precision7 (novel contact lens), and recent pipeline-accretive M&A (STAAR, LumiThera, Voyager) provide significant near

and medium-term opportunities for share gain, mix improvement, and new market entry, underpinning upside to both revenue and net margins as these innovations scale.

Read the complete narrative.

Want to see what is baked into that CHF76.62 fair value for Alcon? The narrative leans heavily on compound revenue growth, rising margins, and a richer product mix. Curious how those building blocks translate into the implied future earnings power and valuation multiple.

Result: Fair Value of CHF76.62 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors also need to weigh risks for Alcon, such as ongoing patent litigation costs and competitive pressure in intraocular lenses, which could weaken the bullish narrative.

Find out about the key risks to this Alcon narrative.

Another view on Alcon valuation

The DCF based narrative points to Alcon trading below an estimated fair value of CHF76.62. The picture changes when looking at the current P/E of 54x compared with 27.2x for peers and a fair ratio of 42.3x. That implies valuation risk if sentiment or growth expectations cool.